The Team to End PD:
The Multiplier Effect
By empowering leaders who multiply our investment, PDF empowers the community to work together to solve, treat and end Parkinson's. Our investment to date includes:
- Fellowships for 150 movement disorder specialists who reach an estimated 12,000 patients every year
- Training for 180 nursing faculty who reach 11,000 nursing students every year
- Training for 260 Research Advocates who work with 400 professionals and have helped to enroll 1,200 people in clinical trials seeking better treatments and a cure
Mobilizing Collaboration Toward a Cure
As part of our strategy to end Parkinson’s disease, PDF is not only developing leaders; we are also mobilizing them to work toward the cure — together.
Collaboration is a key to finding a cure. After all, science and care are team efforts. PDF has invested close to $50 million in collaborations since 1957, largely toward teams at PD research centers. Today, we are expanding the opportunities for research, health care and patient leaders to work together.
What We're Doing
- We're funding interdisciplinary teams. For example, at Columbia University Medical Center, where PDF has long funded teams within the field of PD, we are funding teamwork between PD specialists and bioengineers, who are experimenting with ways to design shoe insoles to ease freezing of gait. And at our Research Center at Rush University Medical Center, we are funding an interdisciplinary project that may one day help doctors to predict who will get PD as part of routine colonoscopies.
- PDF is investing in research teams that incorporate insights from people with Parkinson’s through our PAIR Leadership Awards and our Community Choice Research Awards. For the latter, we invite the patient community to identify research priorities and then we engage teams of researchers, health professionals, patients and outside experts (e.g., gastroenterologists and psychiatrists) who can help to address them.
- We are sharing PD science with the entire team. We do this online, in print and most recently, through a partnership with Nature Publishing Group, the world’s leading publisher of scientific journals. The journal, npj Parkinson’s Disease, is freely available to all with the click of a button.